Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Irinotecan Combinations in 2nd Line NSCLC
NCT00139711Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Pfizer. Primary endpoints: Activity of the association of irinotecan and docetaxel and Tolerability of the association of irinotecan and docetaxel. Started Mar 2003; status: completed.
02
Drugs
irinotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00139711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00139711.